Latest Regulatory Approvals News

Proteomics International Laboratories has achieved the prestigious CAP accreditation for its US lab and installed a new mass spectrometry platform, setting the stage for the 2026 launch of its Promarker diagnostic tests in America.

Clarity Pharmaceuticals’ novel diagnostic agent Cu-SAR-bisPSMA has been selected for oral presentation at the prestigious European Association of Urology Congress 2026, following promising Phase II trial results demonstrating superior detection of prostate cancer recurrence.

Forrestania Resources has acquired key tenements at Mt Dimer from Beacon Minerals, significantly expanding its gold exploration footprint in Western Australia’s Southern Cross Domain. The move aligns with the company’s strategy to consolidate and explore highly prospective gold belts.

Infini Resources has strategically expanded its Portland Creek Uranium Project in Newfoundland by acquiring adjacent mineral licences, increasing its landholding by 30% and reinforcing its position in a promising uranium district.

Western Gold Resources has approved the Decision to Mine for its Gold Duke Project, marking a key shift from exploration to production with first gold targeted in early 2026.

European Metals Holdings has released a Definitive Feasibility Study confirming the Cinovec Lithium Project as a long-life, battery-grade lithium carbonate producer strategically positioned to supply Europe's electric vehicle and energy storage sectors.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

BCI Minerals has secured crucial environmental approvals to proceed with its optimized dredging strategy at the Mardie Salt Operation, setting the stage for first salt shipments by late 2026.

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Fenix Resources’ latest Scoping Study outlines a robust plan to ramp up Weld Range iron ore production to 10 million tonnes per annum by 2031, extending mine life to 2042 with significantly reduced costs and strong financial returns.

Hartshead Resources NL has entered a binding agreement for acquisition by ACAM GP Limited, offering shareholders a 133% premium and a clear exit from development risks. The scheme is set for implementation in early 2026, pending approvals.